Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04047251 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma

Name: A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma — clinical trial record (NCT04047251)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1

SponsorFujifilm Pharmaceuticals U.S.A., Inc.

Started2019-11-14

View on ClinicalTrials.gov ↗

To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors including Merkel Cell Carcinoma

Amendment history 2 changes detected by DataLookout

2026-09-03

Primary completion pushed: 2025-12 → 2026-12

2026-09-03

Completion pushed: 2026-07 → 2027-03

Trial Details

NCT Number	NCT04047251
Lead Sponsor	Fujifilm Pharmaceuticals U.S.A., Inc.
Conditions	Advanced Solid Tumors, Merkel Cell Carcinoma
Enrollment	96 participants
Start Date	2019-11-14
Primary Completion	2026-12 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2026-09-02